ESR1 and breast cancer: While AKT1E17K is absent in the breast cancer subset of the Cancer Genome Atlas (TCGA) datasets, it is detected in appropriately 6% of a population of Chinese breast cancer patients and a cohort of endocrine-resistant and ER+ metastatic breast cancer [227, 228].